Largest biotech companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 20 biotech companies in the United States ranked by net assets, at CZK 505.4B, ahead of Biogen (CZK 406.4B) and Amgen (CZK 192.7B). Figures as of 20 Nov 2026, 08:07 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 20
- First
- Gilead SciencesCZK 505.4B
- Median
- CZK 35.7B
- Combined market value
- CZK 16.36T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | CZK 505.4B | CZK 4.6T | CZK 3,707.37 | 1.45% down | 35% up | ||
| 2 | BiogenBIIB · Health Care | CZK 406.4B | CZK 813.3B | CZK 5,501.73 | 1.70% down | 49% up | ||
| 3 | AmgenAMGN · Health Care | CZK 192.7B | CZK 5.28T | CZK 9,769.23 | 1.14% down | 32% up | ||
| 4 | ModernaMRNA · Health Care | CZK 192.6B | CZK 1.8T | CZK 4,437.58 | 1.29% up | 780% up | ||
| 5 | Neurocrine BiosciencesNBIX · Health Care | CZK 72.4B | CZK 352.9B | CZK 3,486.08 | 3.85% down | 17% up | ||
| 6 | VaxcytePCVX · Health Care | CZK 59.8B | CZK 205.7B | CZK 1,299.24 | 0.27% down | 23% up | ||
| 7 | ExelixisEXEL · Health Care | CZK 48.1B | CZK 357.6B | CZK 1,465.54 | 3.60% down | 63% up | ||
| 8 | Bio-TechneTECH · Health Care | CZK 46.9B | CZK 254.2B | CZK 1,618.48 | 0.07% down | 24% up | ||
| 9 | RepligenRGEN · Health Care | CZK 46.9B | CZK 242.3B | CZK 3,791.08 | 1.38% down | 12% up | ||
| 10 | Revolution MedicinesRVMD · Health Care | CZK 36.3B | CZK 767.7B | CZK 3,549.31 | 0.24% down | 129% up | ||
| 11 | Kymera TherapeuticsKYMR · Health Care | CZK 35.2B | CZK 226.9B | CZK 2,657.92 | 1.44% down | 87% up | ||
| 12 | Krystal BiotechKRYS · Health Care | CZK 27.2B | CZK 208.4B | CZK 7,030.94 | 0.15% up | 54% up | ||
| 13 | ImmunovantIMVT · Health Care | CZK 19B | CZK 149.8B | CZK 723.98 | 1.96% down | 46% up | ||
| 14 | CG OncologyCGON · Health Care | CZK 16.8B | CZK 162.9B | CZK 1,823.30 | 2.38% up | 97% up | ||
| 15 | Twist BioscienceTWST · Health Care | CZK 10.5B | CZK 169.4B | CZK 2,484.94 | 4.07% down | 346% up | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | CZK 5.5B | CZK 136.8B | CZK 1,121.36 | 4.94% up | 26% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | CZK 4.9B | CZK 101.1B | CZK 624.46 | 1.44% down | 74% up | ||
| 18 | Kodiak SciencesKOD · Health Care | CZK 3.5B | CZK 142.5B | CZK 2,179.50 | 0.09% up | 399% up | ||
| 19 | Halozyme TherapeuticsHALO · Health Care | CZK 1.1B | CZK 236.1B | CZK 2,071.30 | 2.88% down | 39% up | ||
| 20 | ImmunityBioIBRX · Health Care | -CZK 11.1B | CZK 155.6B | CZK 146.26 | 1.94% down | 232% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2625 CZK).
Questions and answers
Which biotech companies in the United States rank first by net assets?
Gilead Sciences (CZK 505.4B), Biogen (CZK 406.4B) and Amgen (CZK 192.7B) are the top three of the 20 biotech companies in the United States ranked by net assets as of 20 Nov 2026, 08:07 UTC.
How many biotech companies in the United States are in this ranking?
20 are ranked by net assets.
What are these biotech companies in the United States worth together?
The 20 biotech companies in the United States ranked by net assets have a combined market value of CZK 16.36T as of 20 Nov 2026, 08:07 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies in the United States by net assets”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.